Search
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Categories: Drugs Used in DiabetesCurcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceuticalFor centuries, _Curcuma xanthorrhiza_ oil has been used as a traditional medicine due to its antibacterial, antispasmodic, antioxidative, antitumor, anti-inflammatory and protective effects [A33160]. … _Curcuma xanthorrhiza_ is also known as Javanese Turmeric or Temoe Lawak [F114].
Mixtures: BAMBOO SALT Eunganggo Jook Yeom, BAMBOO SALT Eunganggo Jook Yeom ToothpasteDebrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate 2, where nearly 80% of patients taking lebrikizumab either as monotherapy or combination therapy
Categories: Agents for Dermatitis, Excluding CorticosteroidsCobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalMore specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 … Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV).
Categories: Antivirals used in combination for the treatment of HIV infections, Antiinfectives for Systemic UseUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7719] However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive … Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD).
Mixtures: ANORO ELLIPTA 62.5 MCG + 25 MCG KULLANIMA HAZIR INHALASYON TOZU, 3 X 30 DOZCategories: Drugs for Obstructive Airway Diseases, Agents to Treat Airway DiseaseEstradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedEstradiol cypionate is commercially available as Depo-Estradiol, an intramuscular depot injection used for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the treatment … As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Mixtures: OBAT SUNTIK KB IICategories: Hormonal Contraceptives for Systemic UseInfluenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15621ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Mixtures: Influvac Tetra, suspension for injection in pre-filled syringeRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Ospemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause … FDA approved on February 26, 2013.